Granted Patent
B2
US 12,221,417 · App. 18/520,156 · Granted Feb 11, 2025
Salt of omecamtiv mecarbil and process for preparing salt
Inventors:
Sheng Cui (Thousand Oaks, CA); Henry Morrison (Thousand Oaks, CA); Karthik Nagapudi (South San Francisco, CA); Shawn D. Walker (Woodland Hills, CA); Charles Bernard (Moorpark, CA); Karl Bennett Hansen (Cohasset, MA); Neil Fred Langille (Thousand Oaks, CA); Alan Martin Allgeier (Wilmington, DE); Steven Mennen (Boston, MA); Jacqueline C. S. Woo (Sherwood Park, CA)
Assignee:
CYTOKINETICS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.
Claims (4)
1. Omecamtiv mecarbil dihydrochloride salt, wherein the salt is crystalline.
2. The salt of claim 1 , wherein the salt is anhydrous.
3. The salt of claim 2 , wherein the salt is Form B and is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.8±0.2, 8.8±0.2, 14.7±0.2, 17.7±0.2, and 22.3±0.2° 2θ using Cu Kα radiation.
4. The salt of claim 3 , wherein the XRPD pattern further comprises peaks at 9.6±0.2, 13.5±0.2, 19.2±0.2, and 26.2±0.2° 2θ using Cu Kα radiation.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2024
From: AMGEN INC.
To: CYTOKINETICS, INC.
Reel/Frame 067889/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2024
From: MORGAN, BRADLEY PAUL; MUCI (DECEASED), ALEX
To: CYTOKINETICS, INC.
Reel/Frame 068105/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2024
From: ALLGEIER, ALAN MARTIN; BERNARD, CHARLES; CUI, SHENG; HANSEN, KARL BENNETT; LANGILLE, NEIL FRED; MENNEN, STEVEN; MORRISON, HENRY; NAGAPUDI, KARTHIK; WALKER, SHAWN D.; WOO, JACQUELINE C.S.
To: AMGEN INC.
Reel/Frame 068105/0219 →
Continuity (7)
References Cited (173)
US 6531469B1
· Rieu et al.
· 2003
[cited by applicant]
US 7507735B2
· Morgan et al.
· 2009
[cited by applicant]
US 7989455B2
· Morgan et al.
· 2011
[cited by applicant]
US 8101617B2
· Morgan et al.
· 2012
[cited by applicant]
US 8110595B2
· Morgan et al.
· 2012
[cited by applicant]
US 8445495B2
· Morgan et al.
· 2013
[cited by applicant]
US 8513257B2
· Morgan et al.
· 2013
[cited by applicant]
US 8871768B2
· Morgan et al.
· 2014
[cited by applicant]
US 8871769B2
· Morgan et al.
· 2014
[cited by applicant]
US 9150564B2
· Morgan et al.
· 2015
[cited by applicant]
US 9643925B2
· Morgan et al.
· 2017
[cited by applicant]
US 9895308B2
· Caldwell
· 2018
[cited by examiner]
US 9951015B2
· Bi
· 2018
[cited by examiner]
US 9988354B2
· Cui
· 2018
[cited by examiner]
US 20050096296A1
· Fikstad et al.
· 2005
[cited by applicant]
US 20070161617A1
· Morgan et al.
· 2007
[cited by applicant]
US 20070208000A1
· Morgan et al.
· 2007
[cited by applicant]
US 20090192168A1
· Muci et al.
· 2009
[cited by applicant]
US 20180312469A1
· Cui et al.
· 2018
[cited by applicant]
US 20200079736A1
· Cui et al.
· 2020
[cited by applicant]
US 20200108076A1
· Scott et al.
· 2020
[cited by applicant]
US 20200331859A1
· Cui et al.
· 2020
[cited by applicant]
US 20210198203A1
· Morgan et al.
· 2021
[cited by applicant]
US 20230044617A1
· Cui et al.
· 2023
[cited by applicant]
US 20230090391A1
· Bi
· 2023
[cited by examiner]
CN 101035525A
· 2007
[cited by applicant]
JP 2002535329A
· 2002
[cited by applicant]
JP 2005507909A
· 2005
[cited by applicant]
JP 2007510658A
· 2007
[cited by applicant]
JP 2008503467A
· 2008
[cited by applicant]
JP 2009516000A
· 2009
[cited by applicant]
JP 2009519951A
· 2009
[cited by applicant]
JP 2011520837A
· 2011
[cited by applicant]
JP 2016502348A
· 2016
[cited by applicant]
WO 2003032956A1
· 2003
[cited by applicant]
WO 2003032965A2
· 2003
[cited by applicant]
WO 2005041929A1
· 2005
[cited by applicant]
WO 2006009726A2
· 2006
[cited by applicant]
WO 2006009726A3
· 2006
[cited by applicant]
WO 2007054975A1
· 2007
[cited by applicant]
WO 2007059500A2
· 2007
[cited by applicant]
WO 2007070683A2
· 2007
[cited by applicant]
WO 2007059500A3
· 2007
[cited by applicant]
WO 2009138438A1
· 2009
[cited by applicant]
WO 2014085336A1
· 2014
[cited by applicant]
WO 2014152270A1
· 2014
[cited by applicant]
WO 2020011626A1
· 2020
[cited by applicant]
WO 2020014406A1
· 2020
[cited by applicant]
WO 2021053175A1
· 2021
[cited by applicant]
WO 2021053189A1
· 2021
[cited by applicant]
WO 2021070123A1
· 2021
[cited by applicant]
WO 2021070124A1
· 2021
[cited by applicant]
WO 2021136477A1
· 2021
[cited by applicant]
WO 2022177927A1
· 2022
[cited by applicant]
Amendment in Response to Non-Final Office Action under 37 C.F.R. 1.111, dated Feb. 2, 2017 for U.S. Appl. No. 14/773,436, filed Sep. 8, 2015, 6 pages.
[cited by applicant]
Anonymous. (2021). “Technical Report on Effects of OM Entities: Comparing the Physical Stability of OM Entities,” as submitted by patent proprietor Amgen and Cytokinetics, Inc. in a letter dated Aug. 1, 2021, 22 pages.
[cited by applicant]
Badawy, S.I.F. et al. (May 2007). “Microenvironmental pH Modulation in Solid Dosage Forms,” Journal of Pharmaceutical Sciences 96(5):948-959.
[cited by applicant]
Brief Communication containing a Letter from the Proprietor of the Patent of Jan. 8, 2021 and Auxiliary Requests 1-7, from the EPO in EP2970123 dated Jan. 19, 2021, 62 pages.
[cited by applicant]
Brief Communication regarding the Oral Proceedings and containing a Letter from the Opponent submitted Dec. 7, 2021, in the Opposition of EP Application No. EP14720369.9/EP2970123, 28 pages.
[cited by applicant]
Brief Communication regarding the Oral Proceedings and containing a Letter from the Proprietor and Auxiliary Request 8-13, submitted Dec. 13, 2021, in the Opposition of EP Application No. EP14720369.9/EP2970123, 47 page…
[cited by applicant]
Brief Communication regarding the Oral Proceedings and containing a Letter from the Proprietor submitted Oct. 15, 2021, in the Opposition of EP Application No. EP14720369.9/EP2970123, 8 pages.
[cited by applicant]
Brittain, H.G. (2008). Theory and Origin of Polymorphism in Polymorphism in Pharmaceutical Solids, Brittain eds Marcel Decker, Inc., NY, NY, pp. 17-18, 4 pages.
[cited by applicant]
Carstensen, Advanced Pharmaceutical Solids, Drugs and Pharmaceutical Sciences, 110 New York: Marcel Dekker, Inc. (2001).
[cited by applicant]
Chawla, G. et al. (Jan.-Mar. 2004). “Challenges in Polymorphism of Pharmaceuticals”, GRIPS 5(1):9-12.
[cited by applicant]
Cleland, J.G.F. et al. (Aug. 20, 2011). “The Effects Of The Cardiac Myosin Activator, Omecamtivmecarbil, On Cardiac Function In Systolic Heart Failure: A Double-Blind, Placebo Controlled, Crossover, Dose-Ranging Phase 2…
[cited by applicant]
COLORCON (2009). “An Introduction to METHOCEL, Premium Cellulose Esthers,” Colorcon, Version 2, 2 pages.
[cited by applicant]
Communication of a Notice Opposition mailed May 20, 2020, signed May 14, 2020, by Opponent Keltie LLP against Granted European Patent Application EP14720369.9/EP2970123, filed by Amgen Inc. and Cytokinetics, 27 pages.
[cited by applicant]
Communication of Summons to attend Oral Proceedings Pursuant to Rule 115(1)EPC (including Annex to the communication) in the opposition of EP Application No. EP14720369.9/EP2970123, mailed Mar. 30, 2021, 11 pages.
[cited by applicant]
Declaration of Chunsheng Qiao for EP 2970123 dated and signed Oct. 14, 2021, 5 pages.
[cited by applicant]
Declaration of Fady Malik for EP 2970123 dated and signed Dec. 13, 2021, 3 pages.
[cited by applicant]
Declaration of Mingda Bi for EP 2970123 dated Jul. 1, 2021, 2 pages.
[cited by applicant]
Declaration under 37 CFR 1.132 by inventor Mingda Bi dated and signed Jan. 12, 2016, for U.S. Appl. No. 14/210,713, filed Mar. 14, 2014, 4 pages.
[cited by applicant]
Declaration Under 37 CFR 1.132 Of Mingda Bi, dated Jan. 12, 2016, 4 pages.
[cited by applicant]
Devane, J. (Mar. 8, 2013). “Impact of IVIVR on Product Development,” in In Vitro-in Vivo Correlations, Young, D. B. et al eds., p. 246, 1 page.
[cited by applicant]
Dow. (Jul. 2000). “Using METHOCEL Cellulose Ethers for Controlled Reliease of Drugs in Hydrophilic Matrix Systems,” WEB Brochure, located at https://www.colorcon.com/products-formulation/all-products/polymers-controlled…
[cited by applicant]
Dow. “Methocel Cellulose Ethers, Technical Handbook”, located at https://cms.chempoint.com/ic/getattachment/2d8a4ff1-a232-46b7-b47d-956f2753cb3b/attachment.aspx last visited on Nov. 5, 2021, 32 pages.
[cited by applicant]
European Search Report and Search Opinion for EP Patent Application No. EP20201011.2, filed Oct. 9, 2020, mailed Apr. 13, 2021, 8 pages.
[cited by applicant]
Grounds of Appeal dated Jun. 20, 2022, for European Patent No. 2970123, Carpmaels & Ransford, Proprietors: Amgen Inc. and Cytokinteics, Inc. and Opponent Keltie LLP, 49 pages.
[cited by applicant]
Grounds of Appeal dated Jun. 20, 2022, for European Patent No. 2970123, Opponent Keltie LLP, Patentee Amgen Inc. And Cytokinetics, Inc., 32 pages.
[cited by applicant]
Gu, C. et al., (2004) Grouping solvents by statistical analysis of solvent property parameters: Implication to polymorph screeninQ. Int. J. Pharmaceut. 283:117-25.
[cited by applicant]
Hellriegel, E.T. et al. (Dec. 1996). “Commentaries Interpatient Variability in Bioavailability is related to the extent of absorption: Implications for the Bioavailability and Bioequivalence Studies,” Clinical Pharmacol…
[cited by applicant]
Hirayama, Organic Crystal production Manual: Principle and Know-How, Maruzen CO. Ltd. Japan (2008), 28 pages, no English abstract available.
[cited by applicant]
Interlocutory Decision in Opposition Proceedings (Art. 101(3)(A) and 106(2) EPC), for European Application No. EP14720369.9/EP2970123, dated Feb. 10, 2022, 74 pages.
[cited by applicant]
International Preliminary Report on Patentability issue date of Sep. 15, 2015, for Patent Application No. PCT/US2014/027104, filed Mar. 14, 2014, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability issue date of Sep. 15, 2015, for Patent Application No. PCT/US2014/027146, filed Mar. 14, 2014, 7 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in connection with International Application No. PCT/US2014/027104, United States Patent Office, dated Mar. 14, 2015, 9 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in connection with International Application No. PCT/US2014/027146, United States Patent Office, dated Mar. 14, 2014, 10 pages.
[cited by applicant]
James, J.S. (Aug. 7, 1998). “Ritonavir Capsule Manufacturing Problems Will Require Switch To Liquid Formulation,” AIDS Treat News 300(1), Abstract Only, 1 page.
[cited by applicant]
Malik, F., curriculum vitae dated Nov. 2021, 13 pages.
[cited by applicant]
Minamivado (Apr. 25, 1984). New pharmaceutics, pp. 102-103 and 232-233, 5 pages.
[cited by applicant]
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
[cited by applicant]
Office Action issued in connection with Japanese Patent Application No. 2016-502348, dated Dec. 12, 2017.
[cited by applicant]
Preliminary Communication about the Results of Oral Proceedings mailed Dec. 16, 2021, for EP Application No. EP14720369.9/EP2970123, 9 pages.
[cited by applicant]
Rowe, R. C. et al. (2006). Handbook of Pharmaceutical Excipient, 5th edition, Pharmaceutical Press, 945 pages.
[cited by applicant]
Second Declaration Under 37 CFR 1.132 of Mingda Bi, dated Jun. 24, 2016, 4 pages.
[cited by applicant]
Siepe et al., (2006) “Strategies for the design of hydrophilic matrix tablets with controlled 1 microenvironmental oH”, Int. J. Pharm., 316(1-2):14-20.
[cited by applicant]
Stahly, (2006) “Journal of Pharmaceutical Science and Technology”, Japan, 66(6):435-439. (No. English Abstract Available).
[cited by applicant]
Teerlink, J.R. (Dec. 2009, e-pub. Feb. 21, 2009). “A novel approach to improve cardiac performance: cardiac myosin activators”, Heart Fail Rev., 14(4):289-298.
[cited by applicant]
Teerlink, J.R. et al. (Aug. 20, 2011). “Dose-Dependent Augmentation Of Cardiac Systolic Function With The Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: A First-In-Man Study,” Lancet 378(9792):667-675.
[cited by applicant]
U.S. Appl. No. 15/898,303, filed Feb. 16, 2018, by William Brett Caldwell et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, …
[cited by applicant]
U.S. Appl. No. 17/176,003, filed Feb. 15, 2021, by Sheng Cui et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
U.S. Appl. No. 18/313,267, filed May 5, 2023, by Narimon Honarpour et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Mnogradova, E.V. et al. (Jul. 11, 2012). “Palladium-Catalyzed Cross-Coupling of Aryl Chlorides and Triflates with Sodium Cyanate: A Practical Synthesis of Unsymmetrical Ureas,” J. Am. Chem. Soc. 134(27):11132-11135, 11 …
[cited by applicant]
Waggoner, P. (2020). “Average Relative Humidity,” Encyclopedia Britannica, as retrieved on Dec. 29, 2020, 4 pages.
[cited by applicant]
WHO (2009). “Stability Testing Of Active Pharmaceutical Ingredients And Finished Pharmaceutical Products,” 43rd Report, Annex 2 in the World Health Organization (WHO) Technical Report Series, No. 953, 34 pages.
[cited by applicant]
Berge, S.M. et al. (Jan. 1977). “Pharmaceuticals Salts,” J. Pharmaceutical Sciences 66(1):1-19.
[cited by applicant]
Caira, M.R. (1998). “Crystalline Polymorphism of Organic Compounds,” in Design of Organic Solids. Topics in Current Chemistry, 198:163-208.
[cited by applicant]
Communication of the Board of Appeals Pursuant to Article 15(1) of the Rules of Procedure of the Board of Appeals, mailed Jan. 19, 2024, for EP Application No. EP14720369.9/EP2970123, 16 pages.
[cited by applicant]
Newman, A. (Sep. 2011). “X-ray Powder Diffraction in Solid Form Screening and Selection”, American Pharmaceutical Review Sep./Oct.(6):44-51.
[cited by applicant]
Reply to Appeal dated Nov. 4, 2022, for European Patent No. 2970123, Carpmaels & Ransford, Proprietors: Amgen Inc. and Cytokinteics, Inc. and Opponent Keltie LLP, 84 pages.
[cited by applicant]
Reply to Notice of Appeal dated Nov. 4, 2022, for European Patent No. 2970123, Opponent Keltie LLP, Patentee Amgen Inc. And Cytokinetics, Inc., 112 pages.
[cited by applicant]
Response to the Summons to Oral Proceedings mailed on Oct. 31, 2023, for EP Application No. EP14720369.9/EP2970123, 4 pages.
[cited by applicant]
U.S. Appl. No. 18/421,849, filed Jan. 24, 2024, by Sheng Cui et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Decision of Technical Board of Appeal, Appeal No. T1107/22-3.3.02 of Mar. 7, 2024, dated Jun. 5, 2024, for European Patent No. 14720369.9/EP2970123, 24 pages.
[cited by applicant]
Minutes of the Oral Proceeding, Appeal No. T1107/22-3.3.02 of Mar. 7, 2024, dated Mar. 13, 2024 for European Patent No. 14720369.9/EP2970123, Annotated Auxiliary Request 14 included, 14 pages.
[cited by applicant]
U.S. Appl. No. 18/642,005, filed Apr. 22, 2024, by Fady Malik et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Cited By (3)